A clinical trial is bringing new hope to the fight against drug-resistant tuberculosis (TB), a recently published study has revealed. The studies, published in ‘The Lancet Infectious Diseases’ and the ...

A vaccine protects more than 100 million infants each year from severe tuberculosis (TB), including the fatal brain swelling ...

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile ...

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile compared to linezolid, with potential to replace this current cornerstone in ...

TMC207 is a first-in-class anti-TB diarylquinoline (also named R207910 or the 'J' compound) with activity against drug-sensitive and drug-resistant TB. TMC207 inhibits the proton pump of ...

New strategies for managing TB-DRESS emphasize personalized care, topical therapies, and selective reintroduction protocols, offering hope for better outcomes in HIV co-infected tuberculosis patients.

Bedaquiline quickly became the key drug in all standard drug-resistant tuberculosis regimens globally.

Bedaquiline quickly became the key drug in all standard drug-resistant tuberculosis regimens globally. Unfortunately, clinical Mycobacterium tuberculosis strains rapidly become resistant to ...

On April 16, 2025, the Stop TB Partnership’s Global Drug Facility (GDF) announced that the price of pretomanid, an antibiotic used in the WHO-recommended combination treatment regimen for ...

The rate of AEs among pediatric patients with presumed TB disease was increased for those who received higher vs lower doses of WHO-recommended first-line treatment.